GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Degree of Financial Leverage

Zura Bio (Zura Bio) Degree of Financial Leverage : -0.16 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Zura Bio's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was -0.16. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Zura Bio's Degree of Financial Leverage or its related term are showing as below:

ZURA's Degree of Financial Leverage is ranked better than
85.12% of 1499 companies
in the Biotechnology industry
Industry Median: 0.96 vs ZURA: -0.16

Zura Bio Degree of Financial Leverage Historical Data

The historical data trend for Zura Bio's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Degree of Financial Leverage Chart

Zura Bio Annual Data
Trend Dec21 Mar22 Dec23
Degree of Financial Leverage
- - -0.02

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.02 -0.02 -0.16

Competitive Comparison of Zura Bio's Degree of Financial Leverage

For the Biotechnology subindustry, Zura Bio's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zura Bio's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Zura Bio's Degree of Financial Leverage falls into.



Zura Bio Degree of Financial Leverage Calculation

Zura Bio's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -1.654 (Mar. 2024) / -11.644 (Mar. 2023) - 1 )/( -63.298 (Mar. 2024) / -9.714 (Mar. 2023) - 1 )
=-0.858/5.5162
=-0.16***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Zura Bio  (NAS:ZURA) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Zura Bio Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Zura Bio's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio (Zura Bio) Business Description

Industry
Traded in Other Exchanges
Address
4225 Executive Square, Suite 600, La Jolla, CA, USA, 92037
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Executives
Parvinder Thiara director, 10 percent owner C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Amit Munshi director C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni director 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kimberly Ann Davis officer: Secretary and General Counsel C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Gary Whale officer: EVP and CTO 2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Theresa Lowry officer: EVP and CHRO 3629 VILLA TERRACE, SAN DIEGO CA 92104
Michael Howell officer: SVP, Translational Medicine 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Hana Immunotherapeutics Llc 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Chris Kim 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Ewon Comfortech Co., Ltd. 10 percent owner 8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Steven J Schoch director 2748 BUSH STREET, SAN FRANCISCO CA 94115
Preston Klassen officer: President and COO 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Cabell officer: EVP and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105